Guggenheim analyst Vamil Divan lowered the firm’s price target on AbbVie (ABBV) to $212 from $221 and keeps a Buy rating on the shares. The ...

As the J.P. Morgan Healthcare Conference started in San Francisco on Monday, AbbVie linked up with Simcere with a $1 billion ...

Shares of AbbVie Inc. ABBV rallied 1.37% to $173.70 Thursday, on what proved to be an all-around rough trading session for ...

By Sneha S K and Christy Santhosh (Reuters) -AbbVie plans to "commit less capital" towards experimental medicines for ...

The schizophrenia drug Emraclidine failed to perform in clinical trials but executives say it can still “play a role.” ...

AbbVie will commit "less capital" towards experimental medicines for psychiatric disease, CEO Robert Michael said at an ...

Leerink Partners analyst David Risinger has reiterated their bullish stance on ABBV stock, giving a Buy rating yesterday.Stay Ahead of the ...

Emraclidine was the centerpiece of AbbVie’s $8.7 billion acquisition of Cerevel in December 2023 but failed two mid-stage ...

Abbvie said on Friday it would record a charge of about $3.5 billion related to its experimental schizophrenia drug, ...

Even after a flurry of corporate updates during the first two days of the J.P. Morgan Healthcare Conference, many more ...

AbbVie Inc. closed $31.77 below its 52-week high ($207.32), which the company reached on October 31st.

Simcere Pharmaceutical said on Monday its unit had granted U.S. drugmaker AbbVie the option to license its new blood cancer ...